Page last updated: 2024-09-05

erlotinib hydrochloride and Cancer, Second Primary

erlotinib hydrochloride has been researched along with Cancer, Second Primary in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	5 (83.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andronis, L; Armoiry, X; Clarke, A; Connock, M; Melendez-Torres, GJ; Royle, P; Tsertsvadze, A	1
Fishbein, M; Marchevsky, A; Reckamp, KL; Saldivar, JS; Scher, KS	1
Berger, MF; Kris, MG; Krug, LM; Ladanyi, M; Pietanza, MC; Rekhtman, N; Riely, GJ; Varghese, AM; Wang, L; Won, HH; Yu, HA; Zakowski, MF	1
Crowder, C; Hamner, JB; Singh, G; White, M	1
Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T	1
Chan, G; Pilichowska, M	1

Reviews

1 review(s) available for erlotinib hydrochloride and Cancer, Second Primary

Article	Year
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and seconda BMC cancer, 2019, Apr-25, Volume: 19, Issue:1 Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasms, Second Primary; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Ramucirumab; Randomized Controlled Trials as Topic	2019

Article

Year

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and seconda

BMC cancer, 2019, Apr-25, Volume: 19, Issue:1

Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasms, Second Primary; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Ramucirumab; Randomized Controlled Trials as Topic

2019

Other Studies

5 other study(ies) available for erlotinib hydrochloride and Cancer, Second Primary

Article	Year
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Sep-01, Volume: 11, Issue:9 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines	2013
Small-cell lung cancers in patients who never smoked cigarettes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Chromogranins; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Rearrangement; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Retinoblastoma Protein; Retrospective Studies; Small Cell Lung Carcinoma; Smoking; Survival Rate; Telomerase; Tumor Suppressor Protein p53	2014
Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma. World journal of surgical oncology, 2015, Sep-30, Volume: 13 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis	2015
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome	2011
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood, 2007, Aug-01, Volume: 110, Issue:3 Topics: Aged; Carcinoma, Small Cell; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines; Remission Induction	2007